Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1 2Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1Neoplasms 1Cancer Pain 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Dronabinol × Clear all
NCT05272865 2023-02-01

Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC

LaSanta S A S

Phase 1/2 Unknown
334 enrolled

Cancer Pain, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡